Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Успешное комбинированное лечение рефрактерной артериальной гипертензии. Клиническое наблюдение
Успешное комбинированное лечение рефрактерной артериальной гипертензии. Клиническое наблюдение
Солнцева Т.Д., Денисова А.Р., Сивакова О.А., Данилов Н.М., Певзнер Д.В., Чазова И.Е. Успешное комбинированное лечение рефрактерной артериальной гипертензии. Клиническое наблюдение. Терапевтический архив. 2021; 93 (9): 1086–1090.
DOI: 10.26442/00403660.2021.09.201035
DOI: 10.26442/00403660.2021.09.201035
DOI: 10.26442/00403660.2021.09.201035
________________________________________________
DOI: 10.26442/00403660.2021.09.201035
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В последние годы отмечается увеличение числа больных артериальной гипертензией, одним из вариантов которой является рефрактерная артериальная гипертензия. Этот неблагоприятный клинический вариант течения артериальной гипертензии в связи с более высоким риском развития сердечно-сосудистых осложнений беспокоит клиницистов, осознающих необходимость лучшего контроля артериального давления. Представленный клинический случай демонстрирует успешное комбинированное лечение рефрактерной гипертензии с использованием антигипертензивной терапии и ренальной денервации.
Ключевые слова: артериальная гипертензия, антигипертензивная терапия, ренальная денервация, радиочастотная денервация, почечные артерии
Keywords: arterial hypertension, antihypertensive therapy, renal denervation, radiofrequency denervation, renal arteries
Ключевые слова: артериальная гипертензия, антигипертензивная терапия, ренальная денервация, радиочастотная денервация, почечные артерии
________________________________________________
Keywords: arterial hypertension, antihypertensive therapy, renal denervation, radiofrequency denervation, renal arteries
Полный текст
Список литературы
1. Forouzanfar MH, Liu P, Roth GA, et al. Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990–2015. JAMA. 2017;317(2):165-82. DOI:10.1001/jama.2016.19043
2. Mills KT, Bundy JD, Kelly TN, et al. Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries. Circulation. 2016;134(6):441-50. DOI:10.1161/CIRCULATIONAHA.115.018912
3. Chia R, Pandey A, Vongpatanasin W. Resistant hypertension-defining the scope of the problem. Prog Cardiovasc Dis. 2020;63(1):46-50. DOI:10.1016/j.pcad.2019.12.006
4. Чазова И.Е., Жернакова Ю.В. от имени экспертов. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Системные гипертензии. 2019;16(1):6-31 [Chazova IE, Zhernakova YuV on behalf of the experts. Clinical guidelines. Diagnosis and treatment of arterial hypertension. Systemic Hypertension. 2019;16(1):6-31 (in Russian)]. DOI:10.26442/2075082X.2019.1.190179
5. Feidakis A, Panagiotou MR, Tsoukakis E, et al. Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers on Acute Kidney Injury in Emergency Medical Admissions. J Clin Med. 2021;10(3):412. DOI:10.3390/jcm10030412
6. Moore PK, Hsu RK, Liu KD. Management of Acute Kidney Injury: Core Curriculum 2018. Am J Kidney Dis. 2018;72(1):136-48. DOI:10.1053/j.ajkd.2017.11.021
7. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41(1):111-88. DOI:10.1093/eurheartj/ehz455
8. Матчин Ю.Г., Григин В.А., Данилов Н.М., и др. Радиочастотная денервация почечных артерий в лечении рефрактерной артериальной гипертонии – результаты годичного наблюдения. Атмосфера. Новости кардиологии. 2013;3:12-8 [Matchin JuG, Grigin VA, Danilov NM, et al. Radiofrequency denervation of the renal arteries in the treatment of refractory arterial hypertension – the results of a one-year follow-up. Atmosphere. Cardiology News. 2013;3:12-8 (in Russian)].
9. Townsend RR, Mahfoud F, Kandzari DE, et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet. 2017; 390:2160-70. DOI:10.1016/S0140-6736(17)32281-X
10. Kandzari DE, Kario K, Mahfoud F, et al. The SPYRAL HTN global clinical trial program: rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON MED) of antihypertensive medications. Am Heart J. 2015;171:82-91. DOI:10.1016/j.ahj.2015.08.021
11. Azizi M, Schmieder RE, Mahfoud F, et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet. 2018;6736:1-11. DOI:10.1016/S0140-6736(18)31082-1
12. Al Raisi SI, Pouliopoulos J, Swinnen J, et al. Renal Artery Denervation in Resistant Hypertension: The Good, The Bad and The Future. Heart Lung Circ. 2020;29(1):94-101. DOI:10.1016/j.hlc.2019.06.723
13. Lauder L, Wolf MA, Scholz SS, et al. Renal Denervation: Is It Ready for Prime Time? Curr Cardiol Rep. 2019;21(8):80. DOI:10.1007/s11886-019-1164-2
2. Mills KT, Bundy JD, Kelly TN, et al. Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries. Circulation. 2016;134(6):441-50. DOI:10.1161/CIRCULATIONAHA.115.018912
3. Chia R, Pandey A, Vongpatanasin W. Resistant hypertension-defining the scope of the problem. Prog Cardiovasc Dis. 2020;63(1):46-50. DOI:10.1016/j.pcad.2019.12.006
4. Chazova IE, Zhernakova YuV on behalf of the experts. Clinical guidelines. Diagnosis and treatment of arterial hypertension. Systemic Hypertension. 2019;16(1):6-31 (in Russian). DOI:10.26442/2075082X.2019.1.190179
5. Feidakis A, Panagiotou MR, Tsoukakis E, et al. Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers on Acute Kidney Injury in Emergency Medical Admissions. J Clin Med. 2021;10(3):412. DOI:10.3390/jcm10030412
6. Moore PK, Hsu RK, Liu KD. Management of Acute Kidney Injury: Core Curriculum 2018. Am J Kidney Dis. 2018;72(1):136-48. DOI:10.1053/j.ajkd.2017.11.021
7. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41(1):111-88. DOI:10.1093/eurheartj/ehz455
8. Matchin JuG, Grigin VA, Danilov NM, et al. Radiofrequency denervation of the renal arteries in the treatment of refractory arterial hypertension – the results of a one-year follow-up. Atmosphere. Cardiology News. 2013;3:12-8 (in Russian).
9. Townsend RR, Mahfoud F, Kandzari DE, et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet. 2017; 390:2160-70. DOI:10.1016/S0140-6736(17)32281-X
10. Kandzari DE, Kario K, Mahfoud F, et al. The SPYRAL HTN global clinical trial program: rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON MED) of antihypertensive medications. Am Heart J. 2015;171:82-91. DOI:10.1016/j.ahj.2015.08.021
11. Azizi M, Schmieder RE, Mahfoud F, et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet. 2018;6736:1-11. DOI:10.1016/S0140-6736(18)31082-1
12. Al Raisi SI, Pouliopoulos J, Swinnen J, et al. Renal Artery Denervation in Resistant Hypertension: The Good, The Bad and The Future. Heart Lung Circ. 2020;29(1):94-101. DOI:10.1016/j.hlc.2019.06.723
13. Lauder L, Wolf MA, Scholz SS, et al. Renal Denervation: Is It Ready for Prime Time? Curr Cardiol Rep. 2019;21(8):80. DOI:10.1007/s11886-019-1164-2
2. Mills KT, Bundy JD, Kelly TN, et al. Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries. Circulation. 2016;134(6):441-50. DOI:10.1161/CIRCULATIONAHA.115.018912
3. Chia R, Pandey A, Vongpatanasin W. Resistant hypertension-defining the scope of the problem. Prog Cardiovasc Dis. 2020;63(1):46-50. DOI:10.1016/j.pcad.2019.12.006
4. Чазова И.Е., Жернакова Ю.В. от имени экспертов. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Системные гипертензии. 2019;16(1):6-31 [Chazova IE, Zhernakova YuV on behalf of the experts. Clinical guidelines. Diagnosis and treatment of arterial hypertension. Systemic Hypertension. 2019;16(1):6-31 (in Russian)]. DOI:10.26442/2075082X.2019.1.190179
5. Feidakis A, Panagiotou MR, Tsoukakis E, et al. Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers on Acute Kidney Injury in Emergency Medical Admissions. J Clin Med. 2021;10(3):412. DOI:10.3390/jcm10030412
6. Moore PK, Hsu RK, Liu KD. Management of Acute Kidney Injury: Core Curriculum 2018. Am J Kidney Dis. 2018;72(1):136-48. DOI:10.1053/j.ajkd.2017.11.021
7. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41(1):111-88. DOI:10.1093/eurheartj/ehz455
8. Матчин Ю.Г., Григин В.А., Данилов Н.М., и др. Радиочастотная денервация почечных артерий в лечении рефрактерной артериальной гипертонии – результаты годичного наблюдения. Атмосфера. Новости кардиологии. 2013;3:12-8 [Matchin JuG, Grigin VA, Danilov NM, et al. Radiofrequency denervation of the renal arteries in the treatment of refractory arterial hypertension – the results of a one-year follow-up. Atmosphere. Cardiology News. 2013;3:12-8 (in Russian)].
9. Townsend RR, Mahfoud F, Kandzari DE, et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet. 2017; 390:2160-70. DOI:10.1016/S0140-6736(17)32281-X
10. Kandzari DE, Kario K, Mahfoud F, et al. The SPYRAL HTN global clinical trial program: rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON MED) of antihypertensive medications. Am Heart J. 2015;171:82-91. DOI:10.1016/j.ahj.2015.08.021
11. Azizi M, Schmieder RE, Mahfoud F, et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet. 2018;6736:1-11. DOI:10.1016/S0140-6736(18)31082-1
12. Al Raisi SI, Pouliopoulos J, Swinnen J, et al. Renal Artery Denervation in Resistant Hypertension: The Good, The Bad and The Future. Heart Lung Circ. 2020;29(1):94-101. DOI:10.1016/j.hlc.2019.06.723
13. Lauder L, Wolf MA, Scholz SS, et al. Renal Denervation: Is It Ready for Prime Time? Curr Cardiol Rep. 2019;21(8):80. DOI:10.1007/s11886-019-1164-2
________________________________________________
2. Mills KT, Bundy JD, Kelly TN, et al. Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries. Circulation. 2016;134(6):441-50. DOI:10.1161/CIRCULATIONAHA.115.018912
3. Chia R, Pandey A, Vongpatanasin W. Resistant hypertension-defining the scope of the problem. Prog Cardiovasc Dis. 2020;63(1):46-50. DOI:10.1016/j.pcad.2019.12.006
4. Chazova IE, Zhernakova YuV on behalf of the experts. Clinical guidelines. Diagnosis and treatment of arterial hypertension. Systemic Hypertension. 2019;16(1):6-31 (in Russian). DOI:10.26442/2075082X.2019.1.190179
5. Feidakis A, Panagiotou MR, Tsoukakis E, et al. Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers on Acute Kidney Injury in Emergency Medical Admissions. J Clin Med. 2021;10(3):412. DOI:10.3390/jcm10030412
6. Moore PK, Hsu RK, Liu KD. Management of Acute Kidney Injury: Core Curriculum 2018. Am J Kidney Dis. 2018;72(1):136-48. DOI:10.1053/j.ajkd.2017.11.021
7. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41(1):111-88. DOI:10.1093/eurheartj/ehz455
8. Matchin JuG, Grigin VA, Danilov NM, et al. Radiofrequency denervation of the renal arteries in the treatment of refractory arterial hypertension – the results of a one-year follow-up. Atmosphere. Cardiology News. 2013;3:12-8 (in Russian).
9. Townsend RR, Mahfoud F, Kandzari DE, et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet. 2017; 390:2160-70. DOI:10.1016/S0140-6736(17)32281-X
10. Kandzari DE, Kario K, Mahfoud F, et al. The SPYRAL HTN global clinical trial program: rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON MED) of antihypertensive medications. Am Heart J. 2015;171:82-91. DOI:10.1016/j.ahj.2015.08.021
11. Azizi M, Schmieder RE, Mahfoud F, et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet. 2018;6736:1-11. DOI:10.1016/S0140-6736(18)31082-1
12. Al Raisi SI, Pouliopoulos J, Swinnen J, et al. Renal Artery Denervation in Resistant Hypertension: The Good, The Bad and The Future. Heart Lung Circ. 2020;29(1):94-101. DOI:10.1016/j.hlc.2019.06.723
13. Lauder L, Wolf MA, Scholz SS, et al. Renal Denervation: Is It Ready for Prime Time? Curr Cardiol Rep. 2019;21(8):80. DOI:10.1007/s11886-019-1164-2
Авторы
Т.Д. Солнцева*, А.Р. Денисова, О.А. Сивакова, Н.М. Данилов, Д.В. Певзнер, И.Е. Чазова
ФГБУ «Национальный медицинский исследовательский центр кардиологии» Минздрава России, Москва, Россия
*tatanasolnceva372@gmail.com
National Medical Research Center of Cardiology, Moscow, Russia
*tatanasolnceva372@gmail.com
ФГБУ «Национальный медицинский исследовательский центр кардиологии» Минздрава России, Москва, Россия
*tatanasolnceva372@gmail.com
________________________________________________
National Medical Research Center of Cardiology, Moscow, Russia
*tatanasolnceva372@gmail.com
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.